Shares of Aclaris Therapeutics (Nasdaq: ACRS) closed down almost 45% at $7.07 yesterday, as the company said its zunsemetinib did not meet its primary and secondary efficacy endpoints in a Phase IIa study evaluating the investigational drug in patients with moderate to severe hidradenitis suppurativa.
Hidradenitis suppurativa, also known as acne inversa, is a chronic skin condition featuring painful nodules and abscesses under the skin that can enlarge and drain pus.
The only drug currently approved to treat the disease is AbbVie’s (NYSE: ABBV) Humira (adalimumab), but Novartis (NOVN: VX) is moving to get its interleukin (IL)-17 therapy Cosentyx (secukinumab) approved as an option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze